MRNA · 10-Q · 2026Q2 · Full report

Product / Drug Pipeline Progress

Moderna, Inc. · 2026-07-31 · Importance 23 · Surprise 24

Moderna reported 26 development candidates across 36 clinical development programs spanning infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its intismeran autogene program, mRNA-4157, is being advanced with Merck in nine Phase 2 and Phase 3 trials covering melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma; five-year Phase 2b melanoma data showed a 49% reduction in recurrence or death versus KEYTRUDA alone. The Phase 3 norovirus vaccine study for mRNA-1403 did not meet statistical criteria for early success at interim analysis, although enrollment of an additional cohort is continuing while the trial remains blinded. The propionic acidemia therapeutic mRNA-3927 has reached target enrollment in a registrational study, while the pivotal-trial decision for mRNA-3705 in methylmalonic acidemia was deferred pending the mRNA-3927 data readout.

Key facts

• Moderna, Inc.'s investigational propionic acidemia therapeutic (mRNA-3927) is in a registrational study and target enrollment has been reached with potential data expected in 2026. source
• Commercial sales of mNEXSPIKE were launched in the third quarter of 2025. source
• Moderna, Inc.'s Phase 3 safety and efficacy study of mRNA-1403 for norovirus did not meet statistical criteria for early success at the Phase 3 interim analysis, and the trial is ongoing and remains blinded while enrolling an additional cohort. source
• As of June 30, 2026, mCOMBRIAX had not been commercialized. source
• Moderna, Inc. presented positive five-year Phase 2b adjuvant melanoma data for intismeran in combination with KEYTRUDA at ASCO 2026 showing a 49% reduction in the risk of recurrence or death compared to KEYTRUDA alone. source
• Moderna, Inc. currently has four approved products as of June 30, 2026: Spikevax, mNEXSPIKE, mRESVIA, and mCOMBRIAX (mCOMBRIAX has EC authorization). source
• As of June 30, 2026 Moderna, Inc. has 36 development programs and 26 development candidates across its clinical studies. source